Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
Express Scripts
Moodys
AstraZeneca

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TERIFLUNOMIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Teriflunomide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00134563 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed Sanofi Phase 3 2004-09-01 The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS). Secondary objectives were: - to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale [EDSS], the burden of disease as measured by Magnetic Resonance Imaging [MRI] and patient-reported fatigue; - to evaluate the safety and tolerability of teriflunomide.
NCT00228163 Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses Completed Sanofi Phase 2 2002-01-01 The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.
NCT00475865 Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis Completed Sanofi Phase 2 2007-04-01 The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable dose of Glatiramer Acetate [GA]. The secondary objectives were: - to estimate the effect of the 2 doses of Teriflunomide, compared to placebo, in combination with a stable dose of GA on Magnetic Resonance Imaging [MRI] parameters, relapse rate and patient-reported fatigue; - to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of GA.
NCT00489489 Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis Completed Sanofi Phase 2 2007-05-01 The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide administered once daily for 24 weeks, compared with placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable dose of interferon-β [IFN-β]. Secondary objectives were: - to estimate the effects of the 2 doses of teriflunomide, compared to placebo, in combination with a stable dose of IFN-β on Magnetic Resonance Imaging [MRI] parameters, relapse rate and patient-reported fatigue; - to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of IFN-β.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teriflunomide

Condition Name

Condition Name for Teriflunomide
Intervention Trials
Multiple Sclerosis 21
Relapsing Remitting Multiple Sclerosis 2
Relapsing Multiple Sclerosis (RMS) 2
Relapsing Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Teriflunomide
Intervention Trials
Multiple Sclerosis 29
Sclerosis 26
Multiple Sclerosis, Relapsing-Remitting 4
Multiple Myeloma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Teriflunomide

Trials by Country

Trials by Country for Teriflunomide
Location Trials
United States 169
Canada 21
Germany 15
United Kingdom 13
France 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Teriflunomide
Location Trials
Florida 11
Ohio 9
Texas 8
Tennessee 8
New York 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Teriflunomide

Clinical Trial Phase

Clinical Trial Phase for Teriflunomide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Teriflunomide
Clinical Trial Phase Trials
Completed 16
Recruiting 10
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Teriflunomide

Sponsor Name

Sponsor Name for Teriflunomide
Sponsor Trials
Sanofi 17
Genzyme, a Sanofi Company 4
Centre Hospitalier Universitaire de Nice 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Teriflunomide
Sponsor Trials
Industry 27
Other 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Dow
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.